Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Narrative) (Details)

v2.4.1.9
Summary of Significant Accounting Policies (Narrative) (Details) (USD $)
3 Months Ended
Mar. 31, 2015
Accounting Policies [Abstract]  
Fair value of notes payable $ 39,300,000us-gaap_NotesPayableFairValueDisclosure
Derivative liabilities 63,000us-gaap_DerivativeLiabilities
Lymphoseek license revenue $ 2,000,000us-gaap_DeferredRevenue
Deferred revenue recognition period 2 years